Press release
Essential Thrombocythemia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Essential Thrombocythemia Overview
Essential Thrombocythemia (ET) is a rare blood disease in which the bone marrow produces too many platelets. High numbers of platelets may lead to a thrombus, a blood clot that forms in a blood vessel. This can cause serious health problems such as a stroke, heart attack or pulmonary embolism.
"Essential Thrombocythemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Essential Thrombocythemia Market.
The Essential Thrombocythemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Essential Thrombocythemia Pipeline Report: https://www.delveinsight.com/report-store/essential-thrombocythemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Essential Thrombocythemia treatment therapies with a considerable amount of success over the years. Essential Thrombocythemia Key players such as - Jubilant Therapeutics Inc., Kartos Therapeutics, Inc., Imago BioSciences,Inc., MorphoSys AG, PharmaEssentia Corporation, and others, are developing therapies for the Essential Thrombocythemia treatment
• Essential Thrombocythemia Emerging therapies such as - JBI-802, Navtemadlin + TL-895, Bomedemstat, Pelabresib, P1101, and others are expected to have a significant impact on the Essential Thrombocythemia market in the coming years.
• : In September 2022, Pharma Essentia initiated a trial titled "A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia". In this Phase II trial enrolled patients will receive P1101 over 13 months followed by an extension period
• In August 2020, Pharma Essentia initiated a trial titled "A Phase III, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia"
Route of Administration
Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Essential Thrombocythemia Pipeline Therapeutics Assessment
• Essential Thrombocythemia Assessment by Product Type
• Essential Thrombocythemia By Stage and Product Type
• Essential Thrombocythemia Assessment by Route of Administration
• Essential Thrombocythemia By Stage and Route of Administration
• Essential Thrombocythemia Assessment by Molecule Type
• Essential Thrombocythemia by Stage and Molecule Type
DelveInsight's Essential Thrombocythemia Report covers around 6+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Essential Thrombocythemia Therapeutics Market include:
Key companies developing therapies for Essential Thrombocythemia are - IO Biotech Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Imago BioSciences Inc, Innovent Biologics Inc, Italfarmaco SpA, Johnson & Johnson, MEI Pharma Inc, Millennium Pharmaceuticals Inc, and PharmaEssentia Corp., and others.
Emerging Essential Thrombocythemia Drugs Under Different Phases of Clinical Development Include:
• JBI-802: Jubilant Therapeutics Inc.
• Navtemadlin + TL-895: Kartos Therapeutics, Inc.
• Bomedemstat: Imago BioSciences,Inc.
• Pelabresib: MorphoSys AG
• P1101: PharmaEssentia Corporation
Get a Free Sample PDF Report to know more about Essential Thrombocythemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/essential-thrombocythemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Essential Thrombocythemia Pipeline Analysis:
The Essential Thrombocythemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment.
• Essential Thrombocythemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Essential Thrombocythemia product details are provided in the report. Download the Essential Thrombocythemia pipeline report to learn more about the emerging Essential Thrombocythemia therapies at:
https://www.delveinsight.com/sample-request/essential-thrombocythemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Essential Thrombocythemia Pipeline Market Drivers
• Increased Research and Development Activities
• Updated Diagnostic Criteria
Essential Thrombocythemia Pipeline Market Barriers
• Complications with available treatment options
• Lack of Disease Awareness
Scope of Essential Thrombocythemia Pipeline Drug Insight
• Coverage: Global
• Key Essential Thrombocythemia Companies: Jubilant Therapeutics Inc., Kartos Therapeutics, Inc., Imago BioSciences,Inc., MorphoSys AG, PharmaEssentia Corporation, and others
• Key Essential Thrombocythemia Therapies: JBI-802, Navtemadlin + TL-895, Bomedemstat, Pelabresib, P1101, and others
• Essential Thrombocythemia Therapeutic Assessment: Essential Thrombocythemia current marketed and Essential Thrombocythemia emerging therapies
• Essential Thrombocythemia Market Dynamics: Essential Thrombocythemia market drivers and Essential Thrombocythemia market barriers
Request for Sample PDF Report for Essential Thrombocythemia Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/essential-thrombocythemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Essential Thrombocythemia Report Introduction
2 Essential Thrombocythemia Executive Summary
3 Essential Thrombocythemia Overview
4 Essential Thrombocythemia- Analytical Perspective In-depth Commercial Assessment
5 Essential Thrombocythemia Pipeline Therapeutics
6 Essential Thrombocythemia Late Stage Products (Phase II/III)
7 Essential Thrombocythemia Mid Stage Products (Phase II)
8 Essential Thrombocythemia Early Stage Products (Phase I)
9 Essential Thrombocythemia Preclinical Stage Products
10 Essential Thrombocythemia Therapeutics Assessment
11 Essential Thrombocythemia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Essential Thrombocythemia Key Companies
14 Essential Thrombocythemia Key Products
15 Essential Thrombocythemia Unmet Needs
16 Essential Thrombocythemia Market Drivers and Barriers
17 Essential Thrombocythemia Future Perspectives and Conclusion
18 Essential Thrombocythemia Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Essential Thrombocythemia drugs and therapies- https://www.delveinsight.com/sample-request/essential-thrombocythemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Essential Thrombocythemia Market https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Essential Thrombocythemia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Essential Thrombocythemia Epidemiology https://www.delveinsight.com/report-store/essential-thrombocythemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Essential Thrombocythemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Essential Thrombocythemia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2980014 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Essentia
"Not Blind Faith-But Enlightened Faith: Essentia Offers a New Lens on the Divine …
What if the key to understanding God isn't about blind faith or endless debate? What if it's about thinking clearly, questioning everything, and finding your own path? That's what Essentia: The Ultimate Key to God offers.
HRH Prince Gharios El Chemor of Ghassan Al-Numan VIII doesn't promise easy answers. Instead, he invites readers to question, reflect, and explore faith through a fresh lens. This book is not about telling you what…
Organic Mattress Market Is Booming So Rapidly | Major Giants Astrabeds, Essentia …
The Organic Mattress Market report sheds light on noteworthy influencing trends, emerging issues, and key areas of opportunity that help Organic Mattress manufacturers decide top strategic priorities in next few years. The executive outlook covered in Organic Mattress research reflects the overall industry, with respondents surveyed from different geographies, company sizes, and industry segments. The study starts with an introduction and macro-economic impact on export-import (EXIM), consumption, and production cycle…
Organic Mattress Market Segmentation & Analysis, Industry Growth Forecast 2029| …
Los Angeles, United State: The global Organic Mattress market is comprehensive and accurately presented in the report with the help of detailed market information and data, critical findings, error-free statistics, and reliable forecasts. The report digs deep into important aspects of the global Organic Mattress market, including competition, segmentation, regional expansion, and market dynamics. Each leading trend of the global Organic Mattress market is carefully studied and elaborately presented in…
Organic Mattress Market is Growing Worldwide | Astrabeds, Leggett and Platt, The …
[101 Report Pages] Organic Mattress Market Analysis 2022 (Pre and Post Covid is covered and Report Customization is available) | by Product Type (Organic Innerspring Mattress, Natural Latex Mattress, Plant-based Memory Foam Mattress), Application Type (Construction, Chemical Industry, Manufacturing, Medical, Other), Business scope, Outlook and major players.
The report covers an in-depth analysis of the market composition along with a forecast of the various component and sub-segments of the Organic Mattress…
Meat Ingredients Market Tremendous Growth and Shares | Kerry Group, Ohly, DuPont …
Meat Ingredients Market 2019, recent report published by Data Bridge Market Research provides a unique guidance in thoughtful details regarding the development factors, used a top-down and bottom-up approach to keep it error-free and accurate. The researchers have used primary and secondary methodologies to collect data and its analysis.
With the rising demand for convenience and processed foods and growing adoption of meat ingredients in these products, the market is expected…
Jan 14: Organic Mattress Market 2018-19 Essentia, Lifekind, Kingsdown, Pure Late …
Organic Mattress Market Size
A market study "Global Organic Mattress Market" examines the performance of the Organic Mattress market 2018-19. It encloses an in-depth Research of the Organic Mattress market state and the competitive landscape globally. This report analyzes the potential of Organic Mattress market in the present and the future prospects from various angles in detail.
The Global Organic Mattress Market 2018-19 report includes Organic Mattress market Revenue, market Share, Organic…
